Replacement-Joint Market Shows Signs Of Improvement In 3Q
October 23 2009 - 1:14PM
Dow Jones News
The $11 billion market for replacement hips and knees is showing
signs of improvement after a recession-caused slowdown in
orthopedic procedures, another subtle indication of an economic
recovery.
It may be a slow and steady recovery, but third-quarter reports
from big industry players including Zimmer Holdings Inc. (ZMH) hint
that it's underway. As Zimmer explained, after watching procedure
rates dip three to four percentage points earlier this year, it
looks like there was a one-point recovery in the third quarter.
Procedure volumes are "beginning to thaw in the ortho
reconstructive market," said Joanne Wuensch, an analyst with BMO
Capital Markets.
Replacement joints fix often debilitating arthritic problems,
but people can push off treatment if they're concerned about lost
insurance, high out-of-pocket charges or taking time off work.
These effects have slowed the market this year, although industry
executives have said they believe procedures have been deferred
rather than canceled.
Zimmer's better-than-expected third quarter, reported Thursday,
came on the heels of reports from Stryker Corp. (SYK) and Johnson
& Johnson (JNJ) that also pointed to modest signs of market
recovery. Together those companies comprise the bulk of the
replacement-joint market. Smaller Biomet Inc., which is privately
held and tends to take market share, has also reported for its most
recent fiscal quarter, and the U.K.'s Smith & Nephew Plc (SNN)
reports on Nov. 6.
The view ahead for the sector is still hazy. The industry faces
questions about the effects of health-care reform, potential
changes to a Food and Drug Administration fast-track approval
process commonly used in orthopedics and pressure on prices from
cash-strapped hospitals. Orthopedics companies haven't reported big
increases in price erosion, but they have long been under pressure,
and hospitals appear to be squeezing prices on other devices such
as certain cardiology implants.
Amid all this, signs that the downturn in replacement joint
procedures wasn't too damaging has already fueled a big rebound in
stocks - Zimmer and Stryker shares soared about 71% and 57%,
respectively, between early March and Thursday's close.
The industry can at least face future questions while procedure
growth rates improve, which may not happen rapidly. "We think that
over time you're just going to see a continued progression towards
a more normalized procedure rate," Zimmer Chief Executive David
Dvorak said on the company's earnings call.
Bernstein Research analyst Derrick Sung said the U.S. market
"looks like it has convincingly bottomed with glimmers of recovery
emerging." Meantime, he noted that international markets still look
weak, but don't seem to be worsening.
-By Jon Kamp, Dow Jones Newswires; 617-654-6728;
jon.kamp@dowjones.com
Biomet (NASDAQ:BMET)
Historical Stock Chart
From May 2024 to Jun 2024
Biomet (NASDAQ:BMET)
Historical Stock Chart
From Jun 2023 to Jun 2024